PACTR201804003218439尚未招募未知
Detecting and treating subclinical anthracycline therapy related cardiac dysfunction in low income country
未提供0 个研究点目标入组 50 人开始时间: 2018年3月19日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 50 Year(s)（—）
- 性别
- All
入选标准
- •age: 18 to 50 years
- •Cancer patients who received anthracycline therapy and developed subclinical ATRCD during follow up
排除标准
- •Patient who is taking carvedilol
- •Patient who has any of the conditions:HT,DM,CKD,CAD
- •Patient who has low LVEF
研究者
相似试验
已完成
2 期
A feasibility study of Anthracycline-based regimen followed by Nab-Paclitaxel as adjuvant chemotherapy for breast cancer.(SBCCSG-32)Primary breast cancerJPRN-UMIN000012428Saitama Breast Cancer Clinical Study Group(SBCCSG)40
招募中
1 期
Feasibility study of Anthracycline Based Regimen followed by Nab-Paclitaxel as adjuvant chemotherapy for elderly patients with breast cancerBreast cancerJPRN-UMIN000009267Shimane University Hospital20
已完成
2 期
A feasibility study of sequential Anthracycline-based regimen and Nab-Paclitaxel / Trastuzumab followed by Trastuzumab as postoperative adjuvant chemotherapy for Her2 positive breast cancer.(SBCCSG-22)Primary breast cancerJPRN-UMIN000006085Saitama Breast Cancer Clinical Study Group(SBCCSG)30
已完成
不适用
eutrophil-guided dosing of anthracycline/cyclophosphamide chemotherapy in patients with breast cancer: a feasibility studybreast cancerNL-OMON34109Ikazia Ziekenhuis30
已完成
3 期
Randomized study of anthracycline vs. TS-1 in patients with metastatic or recurrent breast cancerMetastatic or recurrent breast cancerJPRN-UMIN000005449SELECT BC-CONFIRM executive committee200